2022-2023 Seasonal Influenza Testing and Treatment During the COVID-19 Pandemic

Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare

The Centers for Disease Control and Prevention (CDC) has announced a Clinician Outreach and Communication Activity (COCA) Call on November 15th at 2pm ET.

Topic: 2022-2023 Seasonal Influenza Testing and Treatment During the COVID-19 Pandemic

The COVID-19 pandemic disrupted influenza activity during the past two seasons. Since October 2022, influenza activity has increased, signaling an early start to the U.S. influenza season. While it is not possible to predict influenza activity or the severity of the upcoming influenza season in the United States, the Centers for Disease Control and Prevention (CDC) is preparing for co-circulation of influenza and SARS-CoV-2 viruses. While annual influenza vaccination remains the best way to prevent influenza, antiviral medications are an essential addition to vaccination—especially in treating outpatients with suspected or confirmed influenza, people at high risk for influenza complications, those with progressive disease, and hospitalized influenza patients.

During this COCA Call, the presenter will provide an overview of CDC’s recommendations for healthcare providers about influenza diagnostics and the use of antiviral medications for the 2022-2023 influenza season, including considerations during the ongoing COVID-19 pandemic.

Join the call at: https://emergency.cdc.gov/coca/calls/2022/callinfo_111522.asp

The slide set will be available on the day of the call on the COCA Call webpage under Call Materials.

Free Continuing Education (CE) will be offered for this COCA Call.

There will be a web on-demand version of the call available after the live event.